Breast Biopsy Devices Market size was valued at USD 9.4 billion in 2021 and is expected to reach USD 16.4 billion by 2028, at a CAGR of 5.12% during the forecast period 2022-2028. Breast cancer is a disease characterized by the abnormal growth of cells in the breast tissue. Breast biopsy devices are used to diagnose breast cancer by removal of the sample from the breast tissue for laboratory testing. The breast biopsy is preferred when the formation of lumps in the breast or abnormal change in nipples such as congealing, scaling, cellulite, or crusting of the skin. Various types of breast biopsy devices are preferred for breast cancer diagnosis such as vacuum-powered biopsy, fine-needle aspiration, and core needle biopsy among others. The breast biopsy devices market is growing at a significant CAGR over the forecast period. The breast biopsy is mandatory for the diagnosis of breast cancer which cannot be confirmed by breast mammograms. An increase in the global breast cancer incidences (according to World Cancer Research Fund International, about 1.7 Mn new cases were observed in 2012) propels the breast cancer devices market over the forecast period. Acquisitions and mergers, collaborations, patent approvals, and technological advancements are the key strategies followed by the companies for increasing their revenue in the market. For instance, in 2014, Leica Biosystems (Danaher Corporation) acquired Devicor Medical Products for strengthening its breast biopsy devices portfolio. Moreover, In January 2015, Intact Medical Corporation received FDA approval for the minimally-invasive breast biopsy device. In addition, fundraising by start-up companies for the innovation of novel devices also propels the market over the forecast period.